^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoma

    Related cancers:
    22h
    RELATIVITY-069: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=5, Terminated, Bristol-Myers Squibb | Completed --> Terminated
    Trial termination
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    22h
    Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Zhejiang Cancer Hospital
    New trial
    22h
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    23h
    A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients (clinicaltrials.gov)
    P2, N=24, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p)
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    23h
    Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=60, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Aug 2026 --> May 2026
    Enrollment open • Trial initiation date • Pan tumor
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    cyclophosphamide • fludarabine IV
    24h
    Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma (clinicaltrials.gov)
    P1, N=9, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    1d
    FIL_FollVax22: Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance (clinicaltrials.gov)
    P=N/A, N=56, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting
    Enrollment closed
    1d
    Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) (clinicaltrials.gov)
    P=N/A, N=73, Completed, Kyowa Kirin Pharmaceutical Development Ltd | Active, not recruiting --> Completed
    Trial completion
    |
    Poteligeo (mogamulizumab-kpkc)
    1d
    A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants (clinicaltrials.gov)
    P1, N=40, Completed, Ono Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Apr 2026
    Trial completion • Trial completion date
    |
    Velexbru (tirabrutinib)
    2d
    ALLG NBCR: Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ACTRN12612000337875)
    P=N/A, N=10000, Recruiting, Australasian Leukaemia and Lymphoma Group | N=2000 --> 10000
    Enrollment change
    2d
    Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=41, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Columvi (glofitamab-gxbm)
    2d
    JKART-1: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Nov 2025 --> Jul 2027
    Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)